American Cancer Society Guideline for Human Papillon Cervical Cancer and Its Precursors

Ca-A Cancer Journal for Clinicians 57, 7-28 DOI: 10.3322/canjclin.57.1.7

Citation Report

#	Article	IF	CITATIONS
1	HPV Vaccination — More Answers, More Questions. New England Journal of Medicine, 2007, 356, 1991-1993.	13.9	81
2	Moving Forward: Human Papillomavirus Vaccination and the Prevention of Cervical Cancer. Journal of Women's Health, 2007, 16, 1258-1268.	1.5	18
3	<i>CD83</i> Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer. Cancer Research, 2007, 67, 11202-11208.	0.4	32
4	What School Nurses Need to Know About Cervical Cancer, HPV, and the New Vaccine. Journal of School Nursing, 2007, 23, 310-314.	0.9	7
5	Cervical Cancer Screening of Women Living with HIV Infection: A Must in the Era of Antiretroviral Therapy. Clinical Infectious Diseases, 2007, 45, 510-513.	2.9	79
6	Is there a role for Chlamydia trachomatis in the development of cervical cancer?. Reviews in Medical Microbiology, 2007, 18, 55-62.	0.4	0
7	Human papillomavirus vaccines in HIV-positive men and women. Current Opinion in Oncology, 2007, 19, 470-475.	1.1	16
8	Q: Should I get the HPV vaccine?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2007, 20, 59.	0.1	0
9	Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine, 2007, 25, 6437-6446.	1.7	61
10	Human papillomavirus vaccine—recent results and future developments. Current Opinion in Pharmacology, 2007, 7, 470-477.	1.7	8
11	Human papillomavirus and cervical cancer. Lancet, The, 2007, 370, 890-907.	6.3	2,343
12	The burden of human papillomavirus infections and the expected impact of the new vaccines. Expert Review of Vaccines, 2007, 6, 475-477.	2.0	3
13	Impact of the Human Papilloma Vaccine on Cervical Cancer. Journal of Clinical Oncology, 2007, 25, 2975-2982.	0.8	58
14	Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention. Obstetrics and Gynecology Clinics of North America, 2007, 34, 761-781.	0.7	6
15	Cervical Cancer Prevention—Cervical Screening: Science in Evolution. Obstetrics and Gynecology Clinics of North America, 2007, 34, 739-760.	0.7	177
16	Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer, 2007, 111, 145-153.	2.0	119
17	Screening for cervical cancer-controversy and contention or thoughtful analysis. Cancer, 2007, 111, 143-144.	2.0	1
18	Cancer Screening in the United States, 2007: A Review of Current Guidelines, Practices, and Prospects. Ca-A Cancer Journal for Clinicians, 2007, 57, 90-104.	157.7	258

#	Article	IF	CITATIONS
19	Cancer Incidence, Mortality, and Associated Risk Factors Among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities. Ca-A Cancer Journal for Clinicians, 2007, 57, 190-205.	157.7	522
20	Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer, 2007, 7, 164.	1.1	168
21	Gynecological cytology: Too old to be a pop star but too young to die. Diagnostic Cytopathology, 2007, 35, 672-673.	0.5	13
22	Human papillomavirus testing for primary cervical cancer screening. Current Oncology Reports, 2008, 10, 533-537.	1.8	5
23	Human papillomavirus vaccine and cervical cancer prevention. Clinical and Translational Oncology, 2008, 10, 804-811.	1.2	3
25	Preparing our profession for the future. Cancer, 2008, 114, 67-70.	2.0	0
26	Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113, 1980-1993.	2.0	121
27	Human papillomavirus and cervical cancer behavioral surveillance in the US. Cancer, 2008, 113, 3013-3030.	2.0	29
28	Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer, 2008, 113, 3031-3035.	2.0	17
29	A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US. Cancer, 2008, 113, 2995-3003.	2.0	49
30	Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. International Journal of Cancer, 2008, 122, 244-246.	2.3	53
31	The Quadrivalent Human Papillomavirus Vaccine: Potential Factors in Effectiveness. Journal of Midwifery and Women's Health, 2008, 53, 188-194.	0.7	0
32	The clinical content of preconception care: immunizations as part of preconception care. American Journal of Obstetrics and Gynecology, 2008, 199, S290-S295.	0.7	29
33	Assessing Mandatory HPV Vaccination: Who Should Call the Shots?. Journal of Law, Medicine and Ethics, 2008, 36, 384-395.	0.4	31
34	Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. British Journal of Cancer, 2008, 99, 225-229.	2.9	147
35	Distribution and clinical significance of human papillomavirus subtypes in Shenzhen city, People's Republic of China. International Journal of Gynecological Cancer, 2008, 18, 295-299.	1.2	10
36	The future of vaccines for cervical cancer. Gynecologic Oncology, 2008, 109, S48-S56.	0.6	18
37	The current and future role of screening in the era of HPV vaccination. Gynecologic Oncology, 2008, 109, S31-S39.	0.6	28

		CITATION REPORT	
#	Article	IF	CITATIONS
38	Age considerations when vaccinating against HPV. Gynecologic Oncology, 2008, 109, S40-S47.	0.6	42
39	Human papillomavirus vaccine efficacy: Aligning expectations with reality. Gynecologic Oncology, 2008, 111, 1-2.	0.6	40
40	Cancer Screening in the United States, 2008: A Review of Current American Cancer Society Guidelines and Cancer Screening Issues. Ca-A Cancer Journal for Clinicians, 2008, 58, 161-179.	157.7	176
42	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]. Drugs, 2008, 68, 359-372.	4.9	81
43	Human Papillomavirus and Vaccination. Mayo Clinic Proceedings, 2008, 83, 701-707.	1.4	23
45	EUROGIN 2007 roadmap on cervical cancer prevention. Vaccine, 2008, 26, A1-A3.	1.7	1
47	Using risk factors to predict human papillomavirus infection: Implications for targeted vaccination strategies in young adult women. Vaccine, 2008, 26, 1111-1117.	1.7	25
48	A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine, 2008, 26, 1387-1396.	1.7	46
49	Modeling Cervical Cancer Prevention in Developed Countries. Vaccine, 2008, 26, K76-K86.	1.7	102
50	Prophylactic HPV vaccines: New interventions for cancer control. Vaccine, 2008, 26, 6244-6257.	1.7	58
51	Challenges in anti-infective therapy for skin conditions: part 1. Expert Review of Dermatology, 2008, 3, 367-394.	0.3	1
52	Cervical cancer vaccine in Pakistan: let's start thinking. International Journal of Infectious Diseases, 2008, 12, 217.	1.5	0
53	Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer. Obstetrics and Gynecology Clinics of North America, 2008, 35, 519-536.	0.7	82
54	Sexually Transmitted Infections. Urologic Clinics of North America, 2008, 35, 33-46.	0.8	8
55	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, ASO4 Adjuvanted, Adsorbed) [Cervarix???]???. BioDrugs, 2008, 22, 205-208.	2.2	11
56	Understanding Human Papillomavirus. American Journal of Health Education, 2008, 39, 15-24.	0.3	12
57	Infection with Human Papillomavirus and HIV among Young Women in Kampala, Uganda. Journal of Infectious Diseases, 2008, 197, 555-562.	1.9	47
58	Human papillomavirus vaccine and cervical cancer prevention: Practice and policy implications for pharmacists. Journal of the American Pharmacists Association: JAPhA, 2008, 48, e1-e16.	0.7	10

#	Article	IF	CITATIONS
59	Health and Economic Implications of HPV Vaccination in the United States. New England Journal of Medicine, 2008, 359, 821-832.	13.9	317
60	Human papillomavirus disease and vaccines. American Journal of Health-System Pharmacy, 2008, 65, 2105-2112.	0.5	30
61	Human papillomavirus vaccine: Are the concerns unfounded?. American Journal of Health-System Pharmacy, 2008, 65, 2150-2151.	0.5	7
62	Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. Journal of General Virology, 2008, 89, 148-157.	1.3	28
63	Human Papillomavirus Vaccine Legislation in Kentucky. Policy, Politics, and Nursing Practice, 2008, 9, 40-49.	0.8	4
64	Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types) Tj ETQq1 1 0	.784314 r	gBT (Overlo <mark>c</mark> i
65	Human Papillomavirus and Vaccination. Mayo Clinic Proceedings, 2008, 83, 701-707.	1.4	25
66	American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. Yearbook of Dermatology and Dermatologic Surgery, 2008, 2008, 145-146.	0.0	4
67	Trade-offs in Cervical Cancer Prevention. Archives of Internal Medicine, 2008, 168, 1881.	4.3	52
68	Acceptance of Human Papillomavirus Vaccine by Gynecologists in an Urban Setting. Journal of Lower Genital Tract Disease, 2008, 12, 118-121.	0.9	14
69	Cervical Cancer Screening Among Immigrants and Ethnic Minorities. Journal of Lower Genital Tract Disease, 2008, 12, 232-241.	0.9	256
70	Mandating a Human Papillomavirus Vaccine: An Investigation into Whether Such Legislation is Constitutional and Prudent. American Journal of Law and Medicine, 2008, 34, 65-84.	0.5	4
71	A review of topotecan in combination chemotherapy for advanced cervical cancer. Therapeutics and Clinical Risk Management, 2008, Volume 4, 213-218.	0.9	28
72	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	0.4	1
73	Human Papillomavirus. , 2009, , 469-496.		1
74	Management strategies and cost effectiveness in the prevention of cervical cancer. ClinicoEconomics and Outcomes Research, 2009, 1, 17.	0.7	2
75	AMWA Position Statement: Cervical Cancer Prevention. Journal of Women's Health, 2009, 18, 153-153.	1.5	2
76	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‣ike Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPVâ€Naive Women Aged 16–26 Years. Journal of Infectious Diseases, 2009, 199, 926-935.	1.9	528

#	Article	IF	CITATIONS
77	Commentary on Statement on HPV DNA Test Utilization. American Journal of Clinical Pathology, 2009, 131, 770-773.	0.4	2
78	Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ: British Medical Journal, 2009, 339, b3884-b3884.	2.4	189
79	Should HPV vaccine be given to men?. BMJ: British Medical Journal, 2009, 339, b4127-b4127.	2.4	16
80	Barriers for Hispanic Women in Receiving the Human Papillomavirus Vaccine. Clinical Journal of Oncology Nursing, 2009, 13, 671-675.	0.3	7
81	Memoirs Inspire Effort to Eradicate Human Papillomavirus. Clinical Journal of Oncology Nursing, 2009, 13, 615-616.	0.3	1
82	Cervical and Vaginal Cytology. , 2009, , 1-63.		7
83	Marketing and the HPV Vaccine. JAMA - Journal of the American Medical Association, 2009, 302, 2660.	3.8	1
84	Understanding HPV Disease and Prevention: A Guide for School Nurses. Journal of School Nursing, 2009, 25, 261-269.	0.9	14
85	Vaccine Adherence in Adolescents. Clinical Pediatrics, 2009, 48, 801-811.	0.4	19
86	Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2009, 59, 27-41.	157.7	363
87	American Cancer Society Perspectives on Environmental Factors and Cancer. Ca-A Cancer Journal for Clinicians, 2009, 59, 343-351.	157.7	46
88	The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecologic Oncology, 2009, 114, 360-364.	0.6	36
89	Age-appropriate use of human papillomavirus vaccines in the U.S Gynecologic Oncology, 2009, 114, 365-369.	0.6	28
90	A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecologic Oncology, 2009, 115, 285-289.	0.6	27
91	Cervical dysplasia in immunosuppressed IBD women. Inflammatory Bowel Diseases, 2009, 15, 1774.	0.9	3
92	Human papillomavirus vaccination in survivors of childhood cancer. Cancer, 2009, 115, 5627-5636.	2.0	40
93	Commentary on: Statement on HPV DNA test utilization. Diagnostic Cytopathology, 2009, 37, 471-474.	0.5	1
94	The Nurse's Role in the Prevention of Cervical Cancer Among Underserved and Minority Populations. Journal of Community Health, 2009, 34, 135-143.	1.9	6

#	Article	IF	CITATIONS
95	Cervical cancer prevention by vaccination: nurses' knowledge, attitudes and intentions. Journal of Advanced Nursing, 2009, 65, 499-508.	1.5	52
96	The Challenge of Eliminating Cervical Cancer in the United States: A Story of Politics, Prudishness, and Prevention. Women and Health, 2009, 49, 246-261.	0.4	17
97	Present choices, future outcomes: Anticipated regret and HPV vaccination. Preventive Medicine, 2009, 48, 411-414.	1.6	83
98	Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Preventive Medicine, 2009, 48, 432-437.	1.6	17
99	Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 80, 9-18.	1.0	33
100	High-throughput two-step LNA real time PCR assay for the quantitative detection and genotyping of HPV prognostic-risk groups. Journal of Clinical Virology, 2009, 45, 304-310.	1.6	7
101	European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 47-91.	0.6	757
102	HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia. New England Journal of Medicine, 2009, 361, 271-278.	13.9	102
103	Preventing Cervical Cancer in the Latina Population. Journal of Women's Health, 2009, 18, 1935-1943.	1.5	36
104	Conocimientos, aceptabilidad y actitudes sobre la vacuna contra el VPH en médicos generales, ginecólogos y pediatras en Colombia. Revista Colombiana De CancerologÃa, 2009, 13, 88-98.	0.0	6
105	Requiring Human Papillomavirus Vaccine for Immigrant Women. Obstetrics and Gynecology, 2009, 114, 1135-1139.	1.2	2
106	Commentary on. Journal of Lower Genital Tract Disease, 2009, 13, 131-134.	0.9	3
107	Human papillomavirus vaccines and anal carcinoma. Current Opinion in HIV and AIDS, 2009, 4, 57-63.	1.5	33
108	Public Health Issues Related to HPV Vaccination. Journal of Public Health Management and Practice, 2009, 15, 384-392.	0.7	17
109	Human papillomavirus vaccine: a paradigm shift for pediatricians. Current Opinion in Pediatrics, 2009, 21, 112-121.	1.0	8
111	Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States. Annals of Internal Medicine, 2009, 151, 538.	2.0	81
112	Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiology and Infection, 2009, 137, 794-802.	1.0	4
113	â€~HPV? Never heard of it' Students and the HPV vaccine. British Journal of School Nursing, 2009, 4, 328-334.	0.1	5

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
114	From Human Papillomavirus to Cervical Cancer. Obstetrics and Gynecology, 2010, 116, 177-185.	1.2	67
115	Overexpression of LAPTM4B-35 in Cervical Carcinoma. International Journal of Gynecological Pathology, 2010, 29, 587-593.	0.9	24
117	US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening. Sexual Health, 2010, 7, 338.	0.4	6
118	Biphasic Vesicles: A Novel Topical Drug Delivery System. Journal of Biomedical Nanotechnology, 2010, 6, 543-557.	0.5	17
119	Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates. International Journal of Public Health, 2010, 55, 25-34.	2.7	3
120	Cancer, Culture, and Health Disparities: Time to Chart a New Course?. Ca-A Cancer Journal for Clinicians, 2010, 60, 12-39.	157.7	216
121	Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening. Ca-A Cancer Journal for Clinicians, 2010, 60, 99-119.	157.7	405
122	Sixty Years of CA: A Cancer Journal for Clinicians. Ca-A Cancer Journal for Clinicians, 2010, 60, 345-350.	157.7	97
123	Regression of cervical intraepithelial neoplasia by zerumbone in female Balb/c mice prenatally exposed to diethylstilboestrol: Involvement of mitochondria-regulated apoptosis. Experimental and Toxicologic Pathology, 2010, 62, 461-469.	2.1	40
124	Cervical cancer and human papillomavirus in indigenous Guyanese women. American Journal of Obstetrics and Gynecology, 2010, 202, 626.e1-626.e7.	0.7	9
125	How does public policy impact cervical screening and vaccination strategies?. Gynecologic Oncology, 2010, 119, 175-180.	0.6	10
126	The role of the human papillomavirus (HPV) vaccine in developing countries. International Journal of Dermatology, 2010, 49, 377-379.	0.5	19
127	Factors Influencing Familial Decision-Making Regarding Human Papillomavirus Vaccination. Journal of Pediatric Psychology, 2010, 35, 704-715.	1.1	95
128	Human Papillomavirus Health Policy. Policy, Politics, and Nursing Practice, 2010, 11, 23-28.	0.8	6
129	HPV vaccine acceptance among female Greek students. International Journal of Adolescent Medicine and Health, 2010, 22, 271-3.	0.6	12
130	Molecular Targets and Clinical Cancer Risk Reductive Interventions. Progress in Molecular Biology and Translational Science, 2010, 95, 351-375.	0.9	0
131	Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncology, 2010, 6, 1725-1733.	1.1	7
132	The Prophylactic Role for the Human Papillomavirus Quadrivalent Vaccine in Males. Annals of Pharmacotherapy, 2010, 44, 1314-1318.	0.9	8

#	Article	IF	CITATIONS
133	Geographic Disparity, Area Poverty, and Human Papillomavirus Vaccination. American Journal of Preventive Medicine, 2010, 38, 525-533.	1.6	99
134	Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infectious Diseases, The, 2010, 10, 845-852.	4.6	159
135	Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS). Journal of Women's Health, 2010, 19, 365-370.	1.5	9
136	Prophylactic HPV vaccines: the Finnish perspective. Expert Review of Vaccines, 2010, 9, 45-57.	2.0	11
137	Update on the Chemopreventive Effects of Ginger and its Phytochemicals. Critical Reviews in Food Science and Nutrition, 2011, 51, 499-523.	5.4	196
138	Knowledge about cervical cancer among Polish and Finnish female students. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 156, 212-216.	0.5	6
139	The Importance of HIV Status and Gender When Designing Prevention Strategies for Anal Cancer. Journal of the Association of Nurses in AIDS Care, 2011, 22, 454-464.	0.4	4
140	Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine, 2011, 29, 4238-4243.	1.7	31
141	Health beliefs and attitudes associated with HPV vaccine intention among young gay and bisexual men in the southeastern United States. Vaccine, 2011, 29, 8060-8065.	1.7	82
142	The acceptability of human papillomavirus (HPV) vaccination among women with physical disabilities. Research in Developmental Disabilities, 2011, 32, 2020-2026.	1.2	12
143	Health Belief Model Scale for Cervical Cancer and Pap Smear Test: psychometric testing. Journal of Advanced Nursing, 2011, 67, 428-437.	1.5	139
144	Women's awareness of the human papilloma virus and related health problems. Journal of Advanced Nursing, 2011, 67, 2703-2712.	1.5	3
145	Sexually Transmitted Infections in Women: An Overview. Nursing for Women's Health, 2011, 15, 46-58.	0.3	2
146	Cancer screening in the United States, 2011. Ca-A Cancer Journal for Clinicians, 2011, 61, 8-30.	157.7	291
147	History of human papillomavirus, warts and cancer: What do we know today?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 565-574.	1.4	15
148	The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells. Cellular and Molecular Biology Letters, 2011, 16, 477-92.	2.7	7
149	A Promotora-administered group education intervention to promote breast and cervical cancer screening in a rural community along the U.S.–Mexico border: a randomized controlled trial. Cancer Causes and Control, 2011, 22, 367-374.	0.8	72
150	Correlation of <i>LAPTM4B</i> polymorphisms with cervical carcinoma. Cancer, 2011, 117, 2652-2658.	2.0	34

#	ARTICLE	IF	CITATIONS
151	Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey. Cancer, 2011, 117, 5560-5568.	2.0	43
152	Post-transplant malignancy: reducing the risk in kidney transplant recipients. Expert Opinion on Pharmacotherapy, 2011, 12, 1719-1729.	0.9	10
153	Breast and Cervical Cancer Screening Utilization Among Hispanic Women Living Near the United States-Mexico Border. Journal of Women's Health, 2011, 20, 685-693.	1.5	46
154	Evidence-based clinical guidelines for immigrants and refugees. Cmaj, 2011, 183, E824-E925.	0.9	373
155	Risk Factors for Cervical Cancer in Criminal Justice Settings. Journal of Women's Health, 2011, 20, 1839-1845.	1.5	39
157	Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in First Nation women from Northwest Ontario, Canada: a pilot study. BMJ Open, 2011, 1, e000030-e000030.	0.8	51
158	What do primary care physicians know about cervical cancer and HPV vaccine?. Türkiye Aile Hekimliği Dergisi, 2011, 15, 1-6.	0.4	3
159	Predicting Pediatricians' Communication With Parents About the Human Papillomavirus (HPV) Vaccine: An Application of the Theory of Reasoned Action. Health Communication, 2011, 26, 303-312.	1.8	44
160	Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations?: Table 1. Sexually Transmitted Infections, 2012, 88, 433-435.	0.8	20
161	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 2012, 137, 516-542.	0.4	686
162	Cervical cancer in India and HPV vaccination. Indian Journal of Medical and Paediatric Oncology, 2012, 33, 7-12.	0.1	153
163	Cognitive Testing of Human Papillomavirus Vaccine Survey Items for Parents of Adolescent Girls. Journal of Lower Genital Tract Disease, 2012, 16, 16-23.	0.9	11
164	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 2012, 16, 175-204.	0.9	310
165	Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection. Therapeutic Delivery, 2012, 3, 1005-1017.	1.2	11
166	Cervical Cancer Screening in the United States, 1993–2010: Characteristics of Women Who Are Never Screened. Journal of Women's Health, 2012, 21, 1132-1138.	1.5	51
167	Cosmetic surgery prior to diagnosis of breast cancer. Climacteric, 2012, 15, 195-199.	1.1	Ο
168	Health Beliefs and Practices Related to Cancer Screening Among Arab Muslim Women in an Urban Community. Health Care for Women International, 2012, 33, 45-74.	0.6	98
169	Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ: British Medical Journal, 2012, 344, e1401-e1401.	2.4	244

#	Article	IF	CITATIONS
170	Comparison of Knowledge and Attitudes Toward Human Papillomavirus, HPV Vaccine, Pap Tests, and Cervical Cancer Between US and Peruvian Women. Journal of Lower Genital Tract Disease, 2012, 16, 121-126.	0.9	13
171	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 310-319.	1.0	22
172	Prevention: HPV vaccines. , 2012, , 107-143.		0
173	Building Better Models. Medical Decision Making, 2012, 32, 656-659.	1.2	19
174	Immunizations and pregnancy: An update for pharmacists. Journal of the American Pharmacists Association: JAPhA, 2012, 52, e220-e230.	0.7	3
175	Human papillomavirus vaccination intentions and uptake in college women Health Psychology, 2012, 31, 685-693.	1.3	80
176	Pap Testing, Awareness, and Acceptability of a Human Papillomavirus (HPV) Vaccine Among Chinese American Women. Journal of Immigrant and Minority Health, 2012, 14, 803-808.	0.8	23
177	Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecologic Oncology, 2012, 127, 249-255.	0.6	72
178	Human Papillomavirus Vaccine Use Among Adolescent Girls and Young Adult Women: An Analysis of the 2007 California Health Interview Survey. Journal of Women's Health, 2012, 21, 656-665.	1.5	43
179	Cervical Pap Screening Cytological Abnormalities among HIV-Infected Adolescents in the LEGACY Cohort. Journal of Pediatric and Adolescent Gynecology, 2012, 25, 27-34.	0.3	7
180	Cost-effectiveness of adding vaccination with the ASO4-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health, 2012, 12, 924.	1.2	7
181	Treatment, Follow-up, and Prevention of Papillomavirus Infection and Cervical Cancer. , 2012, , 273-326.		0
182	Assessment of clinical and analytical performance characteristics of an HPV genotyping test. Diagnostic Cytopathology, 2012, 40, 367-373.	0.5	12
183	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 147-172.	157.7	1,022
184	Inter-State Variation in Human Papilloma Virus Vaccine Coverage Among Adolescent Girls in the 50 US States, 2007. Maternal and Child Health Journal, 2012, 16, 102-110.	0.7	18
185	Site-directed mutagenesis of human papillomavirus 18 promoter elements and tissue-specific expression in cervical carcinoma cells. Virus Genes, 2012, 44, 395-402.	0.7	1
186	Young Women's Beliefs Regarding Human Papillomavirus. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2012, 41, 92-102.	0.2	3
187	HPV infections: Can they be eradicated using nanotechnology?. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 131-135.	1.7	10

#	ARTICLE	IF	CITATIONS
188	Cancer screening in the United States, 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 129-142.	157.7	123
189	Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France. International Journal of Public Health, 2012, 57, 149-158.	1.0	1
190	Human papillomavirus vaccines. , 2013, , 235-256.		5
191	Community understanding of the preventability of major health conditions as a measure of health literacy. Australian Journal of Rural Health, 2013, 21, 35-40.	0.7	4
192	The Impact of Genomics on Oncology Nursing. Nursing Clinics of North America, 2013, 48, 585-626.	0.7	8
193	Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. Vaccine, 2013, 32, 33-38.	1.7	9
194	Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. International Journal of Cancer, 2013, 133, 2934-2943.	2.3	43
195	Cancer immunotherapy: are we there yet?. Experimental Hematology and Oncology, 2013, 2, 33.	2.0	22
196	Receipt of human papillomavirus vaccine among privately insured adult women in a U.S. Midwestern Health Maintenance Organization. Preventive Medicine, 2013, 57, 712-714.	1.6	9
197	Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States—Do we need a broader vaccine policy?. Vaccine, 2013, 31, 5500-5505.	1.7	43
198	Social inequalities in adolescent human papillomavirus (HPV) vaccination: A test of fundamental cause theory. Social Science and Medicine, 2013, 82, 115-125.	1.8	117
199	Cancer screening in the United States, 2013. Ca-A Cancer Journal for Clinicians, 2013, 63, 87-105.	157.7	249
200	Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. Journal of Infection, 2013, 66, 207-217.	1.7	209
201	Should highâ€risk adolescents have Papanicolaou tests?. Cancer Cytopathology, 2013, 121, 432-439.	1.4	3
202	The four steps in the prevention of human papillomavirus-associated neoplasia. Archives of Gynecology and Obstetrics, 2013, 288, 979-988.	0.8	4
203	Current update on the treatment of genital warts. Expert Review of Dermatology, 2013, 8, 321-332.	0.3	4
204	Risk Factors for Non-initiation of the Human Papillomavirus Vaccine among Adolescent Survivors of Childhood Cancer. Cancer Prevention Research, 2013, 6, 1101-1110.	0.7	27
205	Development of Culturally Tailored Educational Brochures on HPV and Pap Tests for American Indian Women. Journal of Transcultural Nursing, 2013, 24, 282-290.	0.6	9

#	Article	IF	CITATIONS
206	Understanding how mothers of adolescent girls obtain information about the human papillomavirus vaccine: Associations between mothers' health beliefs, information seeking, and vaccination intentions in an ethnically diverse sample. Journal of Health Psychology, 2013, 18, 926-938.	1.3	24
207	A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Human Vaccines and Immunotherapeutics, 2013, 9, 2285-2295.	1.4	26
208	Using the Health Belief Model in Qualitative Focus Groups to Identify HPV Vaccine Acceptability in College Men. International Quarterly of Community Health Education, 2013, 33, 175-187.	0.4	18
209	Exploring Colposcopists' Attitudes Towards Use of HPV Testing as a Primary Screening Tool for Cervical Cancer in British Columbia. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 657-663.	0.3	3
210	Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma. International Journal of Gynecological Cancer, 2013, 23, 735-742.	1.2	38
211	Modern Molecular and Clinical Approaches to Eradicate HPVMediated Cervical Cancer. , 0, , .		1
212	HPV genotypes in paraffin sections of non-cervical squamous cell carcinoma in Qingdao of China. Oncology Letters, 2013, 5, 1219-1222.	0.8	1
213	Efeito idade-periodo-coorte na mortalidade por cancer do colo uterino. Revista De Saude Publica, 2013, 47, 274-282.	0.7	12
214	Update on prevention and screening of cervical cancer. World Journal of Clinical Oncology, 2014, 5, 744.	0.9	93
215	Equity of access to Pap smears: population-based study in Campinas, São Paulo, Brazil. Revista Brasileira De Epidemiologia, 2014, 17, 136-149.	0.3	7
216	Effect of Crude Polysaccharides from <i>Discorea bulbifera</i> L. on the Liver in the Mice Bearing U14 Cervical Carcinoma. Advanced Materials Research, 0, 989-994, 1044-1047.	0.3	1
217	Financial Strain and Cancer Risk Behaviors among African Americans. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 967-975.	1.1	29
218	Viral Carcinogenesis: Factors Inducing DNA Damage and Virus Integration. Cancers, 2014, 6, 2155-2186.	1.7	105
219	Increasing HPV Vaccination Series Completion Rates via Text Message Reminders. Journal of Pediatric Health Care, 2014, 28, e35-e39.	0.6	76
220	Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumor Biology, 2014, 35, 929-934.	0.8	30
221	Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2014, 64, 30-51.	157.7	167
222	Human papillomavirus vaccine acceptance among young men in Bangalore, India. International Journal of Dermatology, 2014, 53, e486-91.	0.5	16
223	Primary care providers human papillomavirus vaccine recommendations for the medically underserved: A pilot study in U.S. Federally Qualified Health Centers. Vaccine, 2014, 32, 5432-5435.	1.7	13

#	Article	IF	CITATIONS
224	Predictors of Information Seeking about the HPV Vaccine From Parents and Doctors Among Young College Women. Communication Quarterly, 2014, 62, 75-96.	0.7	25
225	Risk of Infections with Biological Agents. Gastroenterology Clinics of North America, 2014, 43, 509-524.	1.0	9
226	Pharmacist authority to provide HPV vaccine: Novel partners in cervical cancer prevention. Gynecologic Oncology, 2014, 132, S3-S8.	0.6	37
227	In vivo imaging of islet transplantation using PLGA nanoparticles containing iron oxide and indocyanine green. Magnetic Resonance in Medicine, 2014, 71, 1054-1063.	1.9	14
228	Cervical cytology screening among low-income, minority adolescents in New York City following the 2009 ACOG guidelines. Preventive Medicine, 2014, 63, 81-86.	1.6	3
229	Insurance Continuity and Human Papillomavirus Vaccine Uptake in Oregon and California Federally Qualified Health Centers. American Journal of Public Health, 2014, 104, e71-e79.	1.5	16
230	Designing and Evaluating a Health Belief Model-Based Intervention to Increase Intent of HPV Vaccination among College Males. International Quarterly of Community Health Education, 2014, 34, 101-117.	0.4	57
231	Ginsenoside-Rg5 induces apoptosis and DNA damage in human cervical cancer cells. Molecular Medicine Reports, 2015, 11, 940-946.	1.1	45
232	Prevalence and predictors of Pap smear cervical epithelial cell abnormality among HIV-positive and negative women attending gynecological examination in cervical cancer screening center at Debre Markos referral hospital, East Gojjam, Northwest Ethiopia. BMC Clinical Pathology, 2015, 15, 16.	1.8	42
233	Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer. Pediatric Blood and Cancer, 2015, 62, 1630-1636.	0.8	15
234	Tanshinone IIA inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Bangladesh Journal of Pharmacology, 2015, 10, 483.	0.1	1
235	Human papilloma virus and its relation to cervical cancer prevention strategies. Pediatric Infectious Disease, 2015, 7, 27-32.	0.1	1
236	Cancer statistics for Hispanics/Latinos, 2015. Ca-A Cancer Journal for Clinicians, 2015, 65, 457-480.	157.7	397
237	Disparities in HPV and Cervical Cancer Screening Between Highly Educated White and Minority Young Women. American Journal of Health Education, 2015, 46, 90-98.	0.3	1
238	Acceptability of human papillomavirus vaccine in mothers from Valencia (Spain). Anales De PediatrÃa (English Edition), 2015, 83, 318-327.	0.1	7
239	Approach and Management of Cervical Cancer. , 2015, , 435-486.		0
240	Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2015, 65, 30-54.	157.7	299
242	Nanotechnology in the management of cervical cancer. Reviews in Medical Virology, 2015, 25, 72-83.	3.9	48

#	Article	IF	CITATIONS
243	Special AT-rich sequence-binding protein 1: a novel biomarker predicting cervical squamous cell carcinoma prognosis and lymph node metastasis. Japanese Journal of Clinical Oncology, 2015, 45, 812-818.	0.6	8
244	Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. British Dental Journal, 2015, 218, 671-677.	0.3	15
245	Promoting HPV Vaccination in Safety-Net Clinics: A Randomized Trial. Pediatrics, 2015, 136, 850-859.	1.0	22
246	A lectin-based diagnostic system using circulating antibodies to detect cervical intraepithelial neoplasia and cervical cancer. Glycobiology, 2016, 26, cwv075.	1.3	14
247	Hyperthermia Selectively Targets Human Papillomavirus in Cervical Tumors via p53-Dependent Apoptosis. Cancer Research, 2015, 75, 5120-5129.	0.4	53
248	Clinical significance of human papillomavirus genotyping. Journal of Gynecologic Oncology, 2016, 27, e21.	1.0	79
249	Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016, 16, 804.	1.1	21
250	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer, 2016, 139, 510-517.	2.3	19
251	Addressing inherited predisposition for breast cancer in transplant recipients. Journal of Surgical Oncology, 2016, 113, 605-608.	0.8	1
252	Human Papillomavirus Vaccination Coverage Among Girls Before 13 Years. Clinical Pediatrics, 2016, 55, 904-914.	0.4	12
253	Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection, 2016, 144, 449-468.	1.0	128
254	Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. Journal of Cancer Survivorship, 2016, 10, 449-456.	1.5	17
255	The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations. Applied Health Economics and Health Policy, 2016, 14, 349-359.	1.0	10
256	Prevention of a Sexually Transmitted Disease versus Prevention of a Serious Female Cancer: Remarkably Divergent Views of HPV Vaccination. Women's Health, 2016, 12, 83-85.	0.7	0
257	A paper-based immunoassay to determine HPV vaccination status at the point-of-care. Vaccine, 2016, 34, 5656-5663.	1.7	10
258	Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. Ca-A Cancer Journal for Clinicians, 2016, 66, 375-385.	157.7	60
259	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2016, 66, 95-114.	157.7	198
260	Rate and predictors of human papillomavirus vaccine uptake among women who have sex with women in the United States, the National Health and Nutrition Examination Survey, 2009–2012. Journal of Clinical Nursing, 2016, 25, 3619-3627.	1.4	5

#	Article	IF	CITATIONS
261	Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening. Oncology Letters, 2016, 12, 887-892.	0.8	16
262	Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination. Sexually Transmitted Diseases, 2016, 43, 438-444.	0.8	8
263	Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology. Human Vaccines and Immunotherapeutics, 2016, 12, 1639-1645.	1.4	2
264	Cancer prevention in HIV-infected populations. Seminars in Oncology, 2016, 43, 173-188.	0.8	42
265	Perceptions of <scp>HPV</scp> and attitudes towards <scp>HPV</scp> vaccination amongst men who have sex with men: A qualitative analysis. British Journal of Health Psychology, 2017, 22, 345-361.	1.9	47
266	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2017, 67, 100-121.	157.7	529
267	Hyaluronic acid binding protein 1 overexpression is an indicator for disease-free survival in cervical cancer. International Journal of Clinical Oncology, 2017, 22, 347-352.	1.0	9
268	Inhibition of cervical cancer cell metastasis by benzothiazole through up-regulation of E-cadherin expression. Microbial Pathogenesis, 2017, 111, 182-186.	1.3	11
269	Variation in Human Papillomavirus Vaccine Uptake and Acceptability Between Female and Male Adolescents and Their Caregivers. Journal of Community Health, 2017, 42, 522-532.	1.9	42
270	Kaempferia parviflora Extract Exhibits Anti-cancer Activity against HeLa Cervical Cancer Cells. Frontiers in Pharmacology, 2017, 8, 630.	1.6	32
271	Opportunities and Challenges of Adolescent and Adult Vaccination Administration Within Pharmacies in the United States. Biomedical Informatics Insights, 2017, 9, 117822261769253.	4.6	29
272	Male reproductive health challenges: appraisal of wives coping strategies. Reproductive Health, 2017, 14, 90.	1.2	24
273	Nucleotide variation in ATG4A and susceptibility to cervical cancer in Southwestern Chinese women. Oncology Letters, 2017, 15, 2992-3000.	0.8	10
274	Therapeutic Cancer Vaccines: How Much Closer Are We?. BioDrugs, 2018, 32, 1-7.	2.2	15
275	Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through the Akt/GSK3β signaling pathway in human cervical cancer cells. Molecular Medicine Reports, 2018, 17, 4811-4816.	1.1	21
276	Uterine Cervical Cancer Screening. , 2018, , .		0
277	Reaching 80% human papillomavirus vaccination prevalence by 2026: How many adolescents need to be vaccinated and what are their characteristics?. Cancer, 2018, 124, 4720-4730.	2.0	4
278	Trends in single women with malignancy of the uterine cervix in United States. Journal of Gynecologic Oncology, 2018, 29, e24.	1.0	7

#	Article	IF	CITATIONS
279	Factors associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon, a cross-sectional study. Vaccine, 2018, 36, 7562-7567.	1.7	19
280	Reversing the Trends toward Shorter Lives and Poorer Health for U.S. Women: A Call for Innovative Interdisciplinary Research. International Journal of Environmental Research and Public Health, 2018, 15, 1796.	1.2	4
281	Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. Molecular Therapy, 2018, 26, 2443-2455.	3.7	43
282	Benefits and Costs of the Women's Health Targets for the Post-2015 Development Agenda. , 2018, , 244-254.		3
283	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2018, 68, 297-316.	157.7	433
284	Applications of systems modelling in obesity research. Obesity Reviews, 2018, 19, 1293-1308.	3.1	33
285	Human Papillomavirus Vaccines. , 2018, , 430-455.e10.		5
286	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
287	Protocol for a systematic review of research on HPV and cervical cancer in Ghana, up until the year 2017: informing research and policy direction on cervical cancer prevention in Ghana. BMJ Open, 2018, 8, e020183.	0.8	1
288	Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo. Biomaterials, 2018, 182, 92-103.	5.7	11
289	Advances in technologies for cervical cancer detection in low-resource settings. Expert Review of Molecular Diagnostics, 2019, 19, 695-714.	1.5	25
290	Patterns of incident genital human papillomavirus infection in women: A literature review and meta-analysis. International Journal of STD and AIDS, 2019, 30, 1246-1256.	0.5	7
291	Exploitation of Neisseria meningitidis Group B OMV Vaccines Against N. gonorrhoeae to Inform the Development and Deployment of Effective Gonorrhea Vaccines. Frontiers in Immunology, 2019, 10, 683.	2.2	30
292	Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Preventive Medicine, 2019, 123, 316-323.	1.6	100
293	Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. Ca-A Cancer Journal for Clinicians, 2019, 69, 184-210.	157.7	448
294	Text and Email Messaging for Increasing Human Papillomavirus Vaccine Completion among Uninsured or Medicaid-insured Adolescents in Rural Eastern North Carolina. Journal of Health Care for the Poor and Underserved, 2019, 30, 1499-1517.	0.4	14
295	Clinical Controversies in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2019, 62, 644-655.	0.6	2
296	Pharmacist insights into adolescent human papillomavirus vaccination provision in the United States. Human Vaccines and Immunotherapeutics, 2019, 15, 1839-1850.	1.4	12

#	Article	IF	CITATIONS
297	Interaction Between Susceptibility Loci in <i>MAVS</i> and <i>TRAF3</i> Genes, and High-risk HPV Infection on the Risk of Cervical Precancerous Lesions in Chinese Population. Cancer Prevention Research, 2019, 12, 57-66.	0.7	2
298	Using the health belief model to assess beliefs and behaviors regarding cervical cancer screening among Saudi women: a cross-sectional observational study. BMC Women's Health, 2019, 19, 6.	0.8	39
299	The understudied half of undergraduates: Risky sexual behaviors among community college students. Journal of American College Health, 2020, 68, 302-312.	0.8	19
300	Impact of the Affordable Care Act on human papillomavirus vaccination initiation among lesbian, bisexual, and heterosexual U.S. women. Health Services Research, 2020, 55, 18-25.	1.0	8
301	Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Global Oncology, 2020, 6, 1510-1518.	0.8	3
302	Cervical Cancer Screening Guidelines in the Postvaccination Era: Review of the Literature. Journal of Oncology, 2020, 2020, 1-14.	0.6	22
303	A hidden Markov model for populationâ€level cervical cancer screening data. Statistics in Medicine, 2020, 39, 3569-3590.	0.8	11
304	Regulation of Biobanks in Italy. Frontiers in Pediatrics, 2020, 8, 415.	0.9	4
305	Patient-Level Factors Associated With Lack of Health Care Provider Recommendation for the Human Papillomavirus Vaccine Among Young Cancer Survivors. Journal of Clinical Oncology, 2020, 38, 2892-2901.	0.8	9
306	Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. Ca-A Cancer Journal for Clinicians, 2020, 70, 274-280.	157.7	93
307	What's New in Vaccine Science. Primary Care - Clinics in Office Practice, 2020, 47, 517-528.	0.7	0
308	Cervical cancer screening behaviors and proximity to federally qualified health centers in South Carolina. Cancer Epidemiology, 2020, 65, 101681.	0.8	4
309	Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. Clinical and Translational Oncology, 2020, 22, 1645-1650.	1.2	8
310	Human Papillomavirus Vaccination Schedule: Adherence Among Commercially Insured Adolescents and Young Adults in the United States, 2011–2017. American Journal of Public Health, 2020, 110, 385-390.	1.5	1
311	Immunization and Moral Hazard: The HPV Vaccine and Uptake of Cancer Screening. Medical Care Research and Review, 2021, 78, 125-137.	1.0	10
312	The Use of Nanobiotechnology in Immunology and Vaccination. Vaccines, 2021, 9, 74.	2.1	15
313	Encapsulating Polyethyleneimine-DNA Nanoplexes into PEGylated Biodegradable Microparticles Increases Transgene Expression In Vitro and Reduces Inflammatory Responses In Vivo. AAPS PharmSciTech, 2021, 22, 69.	1.5	2
314	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLoS Medicine, 2021, 18, e1003534.	3.9	30

#	Article	IF	CITATIONS
315	Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone. Malaria Journal, 2021, 20, 183.	0.8	11
316	The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. Current Medicinal Chemistry, 2021, 28, 893-909.	1.2	23
317	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. British Journal of Cancer, 2021, 125, 313-323.	2.9	29
318	Knowledge on cervical cancer screening and vaccination among females at Oyibi Community. BMC Women's Health, 2021, 21, 148.	0.8	5
320	Prevalence and Genotype Distribution of Human Papillomavirus Infection among 12 076 Iranian Women. International Journal of Infectious Diseases, 2021, 111, 295-302.	1.5	7
321	Monogamy as a Barrier to Human Papillomavirus Catch-Up Vaccination. Journal of Women's Health, 2021, 30, 705-712.	1.5	4
322	Vaccines: Boon or Bane—A Nurse's Outlook. , 2013, , 165-179.		1
323	Lifestyle Factors and Health Risk Behaviors. , 2015, , 325-346.		3
324	Prevention of Sexually Transmitted Infections Among Adolescents. , 2017, , 183-205.		4
325	Lifestyle Interventions to Reduce the Risk of Obesity-Associated Gynecologic Malignancies: A Focus on Endometrial Cancer. Energy Balance and Cancer, 2018, , 137-165.	0.2	2
326	Female reproductive system. , 2011, , 1399-1657.		1
330	Characteristics of Infectious Disease That Raise Distinctive Challenges for Bioethics. , 2009, , 26-40.		1
331	The Ethics of Research in Infectious Disease:. , 2009, , 164-183.		7
332	Vertical Transmission of Infectious Diseases and Genetic Disorders. , 2009, , 184-199.		1
334	A School-Based Human Papillomavirus Vaccination Program in Barretos, Brazil: Final Results of a Demonstrative Study. PLoS ONE, 2013, 8, e62647.	1.1	43
335	The Antiviral Restriction Factors IFITM1, 2 and 3 Do Not Inhibit Infection of Human Papillomavirus, Cytomegalovirus and Adenovirus. PLoS ONE, 2014, 9, e96579.	1.1	67
336	Risk of cancer in patients with genital warts: A nationwide, population-based cohort study in Taiwan. PLoS ONE, 2017, 12, e0183183.	1.1	16
337	Breast cancer: why link early detection to reproductive health interventions in developing countries?. Salud Publica De Mexico, 2009, 51, s220-7.	0.1	18

#	Article	IF	CITATIONS
338	Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Current Drug Delivery, 2011, 8, 307-319.	0.8	30
339	Highly Sensitive Detection and Genotyping of HPV by PCR Multiplex and Luminex Technology in a Cohort of Colombian Women with Abnormal Cytology. The Open Virology Journal, 2011, 5, 70-79.	1.8	14
340	The Digital Distribution of Public Health News Surrounding the Human Papillomavirus Vaccination: A Longitudinal Infodemiology Study. JMIR Public Health and Surveillance, 2015, 1, e2.	1.2	25
341	Developing a Tablet-Based Self-Persuasion Intervention Promoting Adolescent HPV Vaccination: Protocol for a Three-Stage Mixed-Methods Study. JMIR Research Protocols, 2016, 5, e19.	0.5	12
342	HPV Vaccination of Girl Child in India: Intervention for Primary Prevention of Cervical Cancer. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2357-2358.	0.5	7
343	The Anticancer Activity and Mechanisms of Ginsenosides: An Updated Review. EFood, 2020, 1, 226-241.	1.7	20
344	Preventing Cancer with Two Injections, A Clinical Review of the HPV Vaccination. Osteopathic Family Physician, 2019, , 24-29.	0.2	2
345	Awareness of human papilloma virus and cervical cancer prevention among Cypriot female healthcare workers. Ecancermedicalscience, 2019, 13, 978.	0.6	5
346	Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?. Annals of Medical and Health Sciences Research, 2013, 3, 306.	0.8	15
347	Using qualitative methods to develop a contextually tailored instrument: Lessons learned. Asia-Pacific Journal of Oncology Nursing, 2015, 2, 192-202.	0.7	11
348	Prevalence and Genotype Distribution of Cervical Human Papillomavirus DNA in Korean Women: A Multicenter Study. Korean Journal of Pathology, 2009, 43, 342.	1.2	18
349	Human Papillomavirus Vaccine. Journal of the Korean Medical Association, 2008, 51, 144.	0.1	2
350	CerviCal Cytology, HPv DNa aND mrNa – a ComParative StuDy iN 162 PatieNtS. Jornal Brasileiro De Doenças Sexualmente TransmissÃveis, 2012, 24, 79-84.	0.1	1
351	The Human Papillomavirus vaccine: An oncology nursing issue. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2009, 19, 60-64.	0.1	1
352	Knowledge about Cervical Cancer Risk Factors and Pap Smear Testing Behavior among Female Primary Health Care Workers: A Study from South Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6389-6392.	0.5	23
353	Are Primary Health Care Workers Aware of Cervical Cancer Risk?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6669-6671.	0.5	9
354	Vaginal microbiota and viral sexually transmitted diseases. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2013, 25, 443-56.	0.5	44
355	HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg. PeerJ, 2020, 8, e8516.	0.9	1

#	Article	IF	CITATIONS
356	Inequalities in Mortality and Access to Hospital Care for Cervical Cancer—An Ecological Study. International Journal of Environmental Research and Public Health, 2021, 18, 10966.	1.2	1
357	Controlling Chlamydia, Gonorrhea, and Syphilis Through Targeted Screening and Treatment in Correctional Settings. , 2007, , 212-226.		0
358	Human Papillomavirus Testing for Precancerous Lesions of the Cervix. North Carolina Medical Journal, 2007, 68, 127-129.	0.1	1
359	Prevalence of Oncogenic HPV Types in Sardinia (Italy): Implications for the Impact of Prophylactic Anti-HPV Vaccines. American Journal of Infectious Diseases, 2007, 3, 134-141.	0.1	0
360	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2007, 42, 374-377.	0.4	0
362	Human Papillomavirus Vaccination: A Case for Mandatory Immunization?. Journal of Pediatric Pharmacology and Therapeutics, 2008, 13, 47-50.	0.3	2
363	Pandemic Planning and the Justice of Health-Care Distribution. , 2009, , 382-406.		0
364	Closing The Book on Infectious Disease. , 2009, , 60-74.		0
365	Old Wine in New Bottles:. , 2009, , 113-140.		0
366	La vaccination contre le virus du papillome humain—un enjeu des soins infirmiers en oncologie?. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2009, , 1-5.	0.1	0
367	Pandemic Planning. , 2009, , 329-358.		1
368	Should Rapid Tests for Hiv Infection Now Be Mandatory During Pregnancy or In Labor?. , 2009, , 200-228.		0
369	Immunization and the Hpv Vaccine. , 2009, , 248-280.		0
370	The Multiple Perspectives of the <i>Patient as Victim and Vector</i> View. , 2009, , 93-110.		1
371	Embedded Autonomy and the â $\in \infty$ Way-Station Selfâ \in , 2009, , 77-92.		0
372	A Thought Experiment. , 2009, , 283-304.		0
373	The Biological Basics of Infectious Disease. , 2009, , 14-25.		0
374	How Infectious Disease Got Left Out of Bioethics. , 2009, , 41-59.		0

#	Article	IF	CITATIONS
375	Antimicrobial Resistance. , 2009, , 229-247.		0
376	Seeing Infectious Disease as Central. , 2009, , 3-13.		0
377	Compensation and the Victims of Constraint. , 2009, , 359-381.		0
378	From the Magic Mountain to a Dying Homeless Man and His Dog:. , 2009, , 141-163.		0
379	The <i>Patient as Victim and Vector</i> View as Critical and Diagnostic Tool. , 2009, , 461-488.		0
380	Thinking Big. , 2009, , 409-460.		0
381	Constraints in the Control of Infectious Disease. , 2009, , 305-328.		0
383	Commentary on Statement on Human Papillomavirus Test Utilization. Archives of Pathology and Laboratory Medicine, 2009, 133, 1192-1194.	1.2	2
384	Genetics of Hereditary Breast Cancer. , 2010, , 41-51.		0
385	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.		0
386	Prevention of Sexually Transmitted Diseases from Office to Globe. , 2011, , 211-232.		0
387	Prevention of Sexually Transmitted Diseases from Office to Globe. , 2011, , 147-168.		0
388	Laboratory Diagnosis of HPV and its Clinical Use. , 2011, , 539-546.		0
389	EpidEmiological FEaturEs oF papillomatosis causEd by thE human papillomavirus in WomEn attEnding thE basic hEalthcarE clinic in nova iguaçu county, statE oF rio dE JanEiro. Jornal Brasileiro De Doenças Sexualmente TransmissÁveis, 2012, 24, 255-259.	0.1	0
390	Human Papillomavirus Infections and Prevention. , 2012, , 71-74.		0
391	Staying a Step Ahead of Cancer. , 0, , .		0
392	Human Papillomavirus Vaccine and Prevention of Human Papillomavirus-Associated Disease in the USA. , 2013, , 383-400.		0
393	Pap Test Screening among Vertically HIV-Infected Young Women. Advances in Infectious Diseases, 2013, 03, 157-161	0.0	0

#	Article	IF	Citations
394	Intraepithelial Neoplasia of the Lower Genital Tract (Cervix, Vulva):. , 2013, , 653-665.		2
395	Relationship of microsatellite instability with cervical carcinoma. Academic Journal of Second Military Medical University, 2013, 32, 991-995.	0.0	0
396	Cervical Cancer Prevention. , 2014, , 533-556.		1
397	Human Papillomavirus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 199-228.		1
398	Human papilloma virus vaccination: practical guidelines. International Journal of Research in Medical Sciences, 2014, 2, 1799.	0.0	0
399	Human Papilloma Virus and HPV vaccine knowledge among Mustafa Kemal University Medical Students. Acta Medica Anatolia, 2014, 2, 37.	0.1	3
400	Breast Cancer Genetics and Risk Assessment. , 2015, , 1-21.		0
401	Innovations in HPV Vaccination and Roles of Nurses in Cervical Cancer Prevention. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10053-10056.	0.5	3
402	Efficacy and safety of prophylactic human papillomavirus vaccination in healthy males. Reviews in Medical Microbiology, 2015, 26, 143-153.	0.4	1
403	NaprotecnologÃa: ciencia y persona en la infección por el virus del papiloma humano (VPH) en mujeres y preadolescencentes. Persona Y Bioética, 2017, 21, 23-45.	0.2	0
404	Morbility and Mortality for Cervical Cancer in the Isle of Youth, 2003-2015. Obstetrics & Gynecology International Journal, 2018, 9, .	0.0	0
405	Approach and Management of Cervical Cancer. , 2019, , 491-549.		0
406	Decreased expression of the Keap1 gene and its clinicopathological significance in gastric cancer: correlation with promoter DNA methylation. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2019, 178, .	0.0	3
407	HPV infection screening using surface plasmon resonance in women from Kunming (southwest) Tj ETQq1 1 0.78	4314 rgBT 0.6	[/&verlock]
408	Assessment of knowledge, attitude and barriers towards cervical cancer vaccination among Malaysian women. Pharmacien Hospitalier Et Clinicien, 2019, 54, 279-287.	0.3	1
409	Human papillomavirus vaccination: review of the current evidence. Mucosa, 2019, 2, 86-94.	0.3	1
410	The expression of cyclooxygenase-2 in carcinoma of uterine cervix. Clinical Cancer Investigation Journal, 2020, 9, 69.	0.2	0
411	Genomic Epidemiology of Human Papillomavirus (HPV), Prostate Cancer, and Diabetes. Health Information Systems and the Advancement of Medical Practice in Developing Countries, 0, , 43-75.	0.1	0

ARTICLE IF CITATIONS Medical Oncology., 2008, , 528-780. 0 414 Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Reviews in Obstetrics and Gynecology, 2008, 1, 122-8. Epigenetics and epigenetic alterations in pancreatic cancer. International Journal of Clinical and 416 0.5 54 Experimental Pathology, 2009, 2, 310-26. Human papilloma virus and cervical preinvasive disease. Journal of Medicine and Life, 2009, 2, 373-7. 418 Human papillomavirus disease and vaccines in adolescents. Adolescent Medicine: State of the Art 419 0.2 5 Reviews, 2010, 21, 347-63, x-xi. Preventing Hepatitis B-induced Liver Cancer: Implications for Eliminating Health Disparities. Journal of Health Disparities Research and Practice, 2010, 4, 88-99. 1.1 422 Genital warts: a comprehensive review. Journal of Clinical and Aesthetic Dermatology, 2012, 5, 25-36. 0.1 52 Prevalence of HPV Infection and High Risk HPV Genotypes (16, 18), among Monogamous and Polygamous 0.3 Women, In Zabol, Iran. Iranian Journal of Public Health, 2011, 40, 113-21. Molecular Epidemiology of High-Risk Types of Human Papillomaviruses (16, 18) in Pap-Smear, the North 424 0.7 4 East of Iran. Iranian Journal of Cancer Prevention, 2011, 4, 135-40. Advanced Algorithms for Predicting Normal and Weak Immune System Among HPV-infected Women., 2020,,. Cervical Intraepithelial Neoplasia Grade 3 in a HPV-Vaccinated Patient: A Case Report. Medicina 426 4 0.8 (Lithuania), 2022, 58, 339. Fenofibrate Exerts Anticancer Effects on Human Cervical Cancer HeLa Cells via Caspase-Dependent Apoptosis and Cell Cycle Arrest. Gynecologic and Obstetric Investigation, 2022, 87, 79-88. The Leaf Extract of Mitrephora chulabhorniana Suppresses Migration and Invasion and Induces Human Cervical Cancer Cell Apoptosis through Caspase-Dependent Pathway. BioMed Research International, 430 0.9 2 2022, 2022, 1-13. Knowledge of human papilloma virus (HPV), HPV-vaccine and pap smear among adult Saudi women. 0.3 Journal of Family Medicine and Primary Care, 2022, 11, 2989. Recurrent, non-traumatic, non-exertional rhabdomyolysis after immunologic stimuli in a healthy 433 0.7 4 adolescent female: a case report. BMC Pediatrics, 2022, 22, . Estrategias Latinoamericanas para la vacunación contra el virus del papiloma humano – una revisión 434 temÃ;tiča. Hacia La PromociÃ³n De La Salud, 2017, 22, 129-143. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on 436 1.1 5 the Health of Female Subjects With Cystic Fibrosis. Clinical Therapeutics, 2023, 45, 278-289. Advances in nanomedicine for the treatment of infectious diseases caused by viruses. Biomaterials Science, 2023, 11, 3431-3449.

ARTICLE

IF CITATIONS